Drug resistance is uncommon in pregnant women with low viral loads taking zidovudine monotherapy to prevent perinatal HIV transmission
| Autor: | Fiona Cottam, Mark Zuckerman, J Welch, Jane Mullen, Phillip Hay, Annemiek de Ruiter, Siobhan O'Shea, Graham P. Taylor, Phillip Rice, Caroline A. Sabin, Nick Larbalestier, I.L. Chrystie |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Pediatrics
medicine.medical_specialty Anti-HIV Agents Immunology HIV Infections Drug resistance Biology Cohort Studies Zidovudine Acquired immunodeficiency syndrome (AIDS) Pregnancy Drug Resistance Viral medicine Immunology and Allergy Humans Pregnancy Complications Infectious Reverse-transcriptase inhibitor Viral Load medicine.disease biology.organism_classification HIV Reverse Transcriptase Infectious Disease Transmission Vertical Infectious Diseases Lentivirus Cohort Mutation HIV-1 Female Viral disease Viral load medicine.drug |
| Zdroj: | AIDS (London, England). 17(18) |
| ISSN: | 0269-9370 |
| Popis: | Zidovudine monotherapy is used to reduce perinatal HIV transmission in women with low viral loads. There are few data on the risk of drug resistance in this select cohort of women. We determined the prevalence of newly acquired mutations conferring reduced sensitivity to zidovudine after exposure during pregnancy, and found that the development of mutations was uncommon and was restricted to women treated before 1998 who had higher baseline viral loads than those currently recommended monotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|